Inari MedicalNARI
Market Cap: $2.65B
About: Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes; ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism, InThrill system to treat small vessel thrombosis, LimFlow system and others. Geographically, the company generates majority of its revenue from United States and rest from International markets.
Employees: 1,300
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
391% more call options, than puts
Call options by funds: $7.61M | Put options by funds: $1.55M
42% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 36
19% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 73
7% more funds holding
Funds holding: 226 [Q1] → 241 (+15) [Q2]
5% less capital invested
Capital invested by funds: $2.72B [Q1] → $2.58B (-$142M) [Q2]
5.8% less ownership
Funds ownership: 97.8% [Q1] → 92.01% (-5.8%) [Q2]
67% less funds holding in top 10
Funds holding in top 10: 3 [Q1] → 1 (-2) [Q2]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
8 analyst ratings
Leerink Partners Mike Kratky 64% 1-year accuracy 7 / 11 met price target | 3%upside $47 | Market Perform Initiated | 3 Sept 2024 |
Piper Sandler Adam Maeder 60% 1-year accuracy 9 / 15 met price target | 10%upside $50 | Neutral Maintained | 26 Aug 2024 |
Deutsche Bank Pito Chickering 82% 1-year accuracy 9 / 11 met price target | 49%upside $68 | Buy Initiated | 9 Aug 2024 |
Wells Fargo Larry Biegelsen 68% 1-year accuracy 25 / 37 met price target | 43%upside $65 | Overweight Maintained | 31 Jul 2024 |
Truist Securities Richard Newitter 67% 1-year accuracy 29 / 43 met price target | 21%upside $55 | Hold Reiterated | 31 Jul 2024 |
Financial journalist opinion
Based on 3 articles about NARI published over the past 30 days